2 min read
Booth: #69
Date: March 19-20, 2024
Location: ExCel London - Get directions
Event website: https://www.terrapinn.com/congress/advanced-therapies/index.stm
Join us for our presentation & MEET OUR TEAM!
Don't miss Martina Brunati, our Upstream Vector Development Manager, presenting on March 20, from 12:20-13:00 on viral vector manufacturing for gene therapy. We hope to see you there!
Would you like to talk with one of our team members? Interested in learning more about our global network and capabilities? Click the button below or email one of our attending representatives at the event to set up a meeting.
You can also reach out directly to our experts attending the show
Explore our AAV & LVV Platforms
BravoAAV™ and ProntoLVV™ are end-to-end platforms offering a proprietary GOI backbone and plug-and-play templates for any project. Our services include proprietary plasmids, in-house analytical panels, master cell banks, pre-qualified processes and fill and finish services.
Learn about our cell and gene therapy services
Cell Therapy Production and Manufacturing
AGC Biologics’ cell therapy services support every stage of the product journey, from pre-clinical through commercialization. At our Milan and Longmont facilities, we can work with virtually any cell type – including Human Mesenchymal Stem Cells (hMSCs), Exosomes, CD34+, T-Cells, NK Cells, and more.
Using the latest autologous and allogeneic methods, we help your products meet the exact specifications for patients in a clinical or commercial setting.
Plasmid DNA (pDNA) Materials
To support your pDNA needs, AGC Biologics utilizes a customized process based on your specific plasmid and hosting system. We have extensive technical expertise in fermentation, purification, and analytics, and our highly experienced teams routinely manufacture GMP-grade pDNA materials. This work includes starting material for gene therapy, and viral vector manufacturing.
Viral Vector Production and Manufacturing
AGC Biologics scientists have two decades of viral vector-based gene therapy expertise and specialize in adeno-associated viral vectors (AAV), lentiviral vectors (LVV), and retroviral vectors (RVV). Our sites in the U.S. and Italy have supported four commercial products.
Our ready-to-use platform capabilities for AAV and LVV programs are built on cell factories and bioreactors using adherent and suspension processes, designed entirely in-house.
Fill out the form below to request a meeting during the event
